“…(Wang et al, 2017;Liang et al, 2020;Schiapparelli et al, 2020). The drug-peptide conjugates firstly served as prodrugs and would then fabricate into supramolecular nanomedicines by site-selective stimulus, including factors in microenvironment such as different ionic strengths or pH (Cong et al, 2019;Kubota et al, 2020) and temperatures, (Nasrollahi et al, 2018;Ji et al, 2019), upregulated redox molecules namely glutathione, (Xu et al, 2018), hydrogen peroxide and some other reactive oxygen species, (Miao et al, 2013;Wu et al, 2019), and abnormally expressed enzymes like esterases, proteases and phosphatases, (Li et al, 2015;Shi et al, 2018;Wang H et al, 2019), such in-situ SA approach gained success in enhancing the permeability of nanomedicine and increasing the concentration of therapeutic agents at disease sites. (Cai et al, 2017;Cheng et al, 2019a;Feng et al, 2019;Zhou et al, 2019).…”